Production (Stage)
Arrowhead Pharmaceuticals, Inc.
ARWR
$15.13
-$0.26-1.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 542.71M | 2.50M | 0.00 | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 542.71M | 2.50M | 0.00 | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 542.71M | 2.50M | 0.00 | -- | -- |
| SG&A Expenses | 36.09M | 30.71M | 32.56M | 30.84M | 31.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 161.51M | 163.91M | 162.20M | 176.14M | 126.19M |
| Operating Income | 381.20M | -161.41M | -162.20M | -176.14M | -126.19M |
| Income Before Tax | 369.62M | -175.12M | -172.80M | -173.98M | -127.00M |
| Income Tax Expenses | 1.75M | 103.00K | 546.00K | -- | -- |
| Earnings from Continuing Operations | 367.86M | -175.22M | -173.34M | -173.98M | -127.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.58M | 2.13M | 2.81M | 3.18M | 1.70M |
| Net Income | 370.45M | -173.09M | -170.54M | -170.79M | -125.30M |
| EBIT | 381.20M | -161.41M | -162.20M | -176.14M | -126.19M |
| EBITDA | 387.29M | -156.18M | -157.18M | -171.36M | -121.67M |
| EPS Basic | 2.78 | -1.39 | -1.37 | -1.38 | -1.02 |
| Normalized Basic EPS | 1.75 | -0.86 | -0.85 | -0.85 | -0.63 |
| EPS Diluted | 2.75 | -1.39 | -1.37 | -1.38 | -1.02 |
| Normalized Diluted EPS | 1.74 | -0.86 | -0.85 | -0.85 | -0.63 |
| Average Basic Shares Outstanding | 133.36M | 124.85M | 124.36M | 124.20M | 123.29M |
| Average Diluted Shares Outstanding | 134.48M | 124.85M | 124.36M | 124.20M | 123.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |